Valuation: Circio Holding ASA

Market Cap 2.95B 310M 273M 258M 234M 436M 29.74B 442M 3.08B 1.19B 15.19B 1.16B 1.14B 48.58B P/E 2024
0.25x
P/E 2025 -2.65x
Enterprise Value 2.96B 310M 273M 258M 234M 436M 29.77B 442M 3.08B 1.19B 15.2B 1.16B 1.14B 48.61B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
73.72%
Yield 2024 *
-
Yield 2025 -
1 week-8.97%
Current month-16.72%
1 month-24.01%
3 months+41.39%
6 months+31.38%
Current year+824.40%
1 week 9.92
Extreme 9.92
11.2
1 month 9.92
Extreme 9.92
15.7
Current year 0.98
Extreme 0.978
15.7
1 year 0.59
Extreme 0.59
15.7
3 years 0.48
Extreme 0.48
15.7
5 years 0.48
Extreme 0.48
236.7
10 years 0.48
Extreme 0.48
1,017
Manager TitleAgeSince
Chief Executive Officer - 2021-10-19
Director of Finance/CFO 58 2022-03-06
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-30
Director/Board Member 66 2015-09-13
Chairman 64 2020-04-28
Date Insider Type Main position Quantity % Market Cap. Importance
11/30/21 Exercice

Chief Executive Officer

120,000 0.1386%
5/19/21 Buy

Director

21,299 0.0246%
12/3/20 Buy

Chief Technology Officer

10,000 0.0116%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.97%+1,663.94%-8.03% 294M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-3.08%+37.74%+84.21% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-1.94%-14.13%+354.32% 25.73B
+0.57%+3.14%+1.02%-3.92% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+0.02%+49.51%+163.05% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.20%-1.52%+200.09%+147.81% 27.54B
Weighted average by Cap. -0.12%-1.06%+39.87%+125.15%

Financials

2024 2025
Net sales - -
Net income 57.52M 6.03M 5.31M 5.02M 4.55M 8.49M 579M 8.6M 60M 23.18M 296M 22.65M 22.16M 946M -45.91M -4.82M -4.23M -4M -3.63M -6.78M -462M -6.86M -47.88M -18.5M -236M -18.07M -17.68M -755M
Net Debt -972K -102K -89.65K -84.76K -76.92K -143K -9.78M -145K -1.01M -392K -5M -383K -374K -15.98M 2.24M 235K 207K 196K 178K 331K 22.6M 336K 2.34M 905K 11.54M 884K 865K 36.91M
Logo Circio Holding ASA
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Employees
11
Date Price Change Volume
26-09-28 NOK 10.76 +5.91% 5,228,967
26-09-25 NOK 10.16 -1.74% 3,953,975
26-09-24 NOK 10.34 -2.08% 4,927,209
26-09-23 NOK 10.56 +0.76% 5,836,833
26-09-22 NOK 10.48 -4.20% 10,242,365

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRVX Stock